Natera Scores Rare FDA Approval but Shares Drop
Natera shares dropped Friday, even after its Signatera cancer test cleared a major U.S. regulatory hurdle. Some traders were moving out of healthcare growth stocks ahead of the weekend, which weighed on the stock.
